Multiples Myelom - Therapie

Glossar

DSMM = Deutsche Studiengruppe Multiples Myelom

GMMG = German-speaking Myeloma Multicenter Group

OSHO = Ostdeutsche Studiengruppe Hämatologie/Onkologie

TRM = Therapie-bezogene Mortalität

VAD = Vincristin, Doxorubicin, Dexamethason

VID = Vincristin, Idarubicin, Dexamethason

Literatur

• 1 Attal M, Harousseau J L, Stoppa A M. et al. Intergroupe Francais Du Myelome . A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.  N Engl J Med. 1996;  335 91-97
• 2 Barille-Nion S, Barlogie B, Bataille R. et al . Advances in Biology and Therapy of Multiple Myeloma. Hematology.  Am Soc Hematol Educ Program. 2003;  1 248-278
• 3 Bjorkstrand B, Svensson H, Goldschmidt H. et al . Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).  Bone Marrow Transplant. 2001;  27 511-515
• 4 Child J A, Morgan G J, Davies F E. et al . High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.  N Engl J Med. 2003;  348 1875-1883
• 5 Cunningham D, Powles R, Malpas J. et al . A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results.  Br J Haematol. 1998;  102 495-502
• 6 Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients.  Ann Oncol. 2000;  11 1427-1436
• 7 Gahrton G, Svensson H, Cavo M. et al . Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation Centres.  Br J Haematol. 2001;  113 209-216
• 8 Kropff M H, Lang N, Bisping G. et al . Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma.  Br J Haematol. 2003;  122 607-616
• 9 Moreau P, Facon T, Attal M. et al . Comparison of 200 mg/m[2) melphalan and 8 Gy total body irradiation plus 140 mg/m[2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial.  Blood. 2002;  99 731-735
• 10 Myeloma Trialists’ Collaborative Group . Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.  J Clin Oncol. 1998;  16 3832-3842
• 11 Myeloma Trialists’ Collaborative Group . Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients.  Br J Haematol. 2001;  113 1020-1034
• 12 Palumbo A, Triolo S, Argentino C. et al . Dose-intensive melphalan with stem cell support (mel100) is superior to standard treatment in elderly myeloma patients.  Blood. 1999;  94 1248-1253
• 13 Richardson P G, Barlogie B, Berenson J. et al . A phase 2 study of bortezomib in relapsed, refractory myeloma.  N Engl J Med. 2003;  348 2609-2617
• 14 Singhal S, Mehta J, Desikan R. et al . Antitumor activity of thalidomide in refractory multiple myeloma.  N Engl J Med. 1999;  341 1565-1571
• 15 Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma.  Bone Marrow Transplant. 2002;  30 673-679